Skip to search formSkip to main contentSkip to account menu

Rifalazil

Known as: 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin, 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin, benzoxazinorifamycin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
2008
2008
Osteomyelitis represents a challenge to modern medicine. This inflammatory process is accompanied by bone necrosis, and results… 
Highly Cited
2007
Highly Cited
2007
ABSTRACT The incidence and severity of Clostridium difficile-associated disease (CDAD) is increasing, and standard treatment is… 
Highly Cited
2004
Highly Cited
2004
ABSTRACT Although vancomycin and metronidazole effectively treat Clostridium difficile-associated diarrhea and colitis (CDAD… 
Highly Cited
2001
Highly Cited
2001
ABSTRACT Rifalazil, also known as KRM-1648 or benzoxazinorifamycin, is a new semisynthetic rifamycin with a long half-life of… 
1995
1995
We investigated the activity of benzoxazinorifamycin (KRM-1648) against several drug-susceptible and multidrug-resistant strains… 
Highly Cited
1995
Highly Cited
1995
The in vitro and in vivo activities of a new benzoxazinorifamycin, KRM-1648 (KRM), against Mycobacterium tuberculosis were… 
Highly Cited
1992
Highly Cited
1992
Newly synthesized benzoxazinorifamycin, KRM-1648, was studied for its in vivo anti-Mycobacterium avium complex (MAC) activities…